Eli Lilly and Co
Change company Symbol lookup
Select an option...
LLY Eli Lilly and Co
SCLXW Scilex Holding Equity Warrants Exp 11th Oct 2027 *W EXP 10/11/2027
GMBL Esports Entertainment Group Inc
CFRX ContraFect Corp
AAL American Airlines Group Inc
NVDA NVIDIA Corp
AMD Advanced Micro Devices Inc
QQQ Invesco QQQ Trust
AAPL Apple Inc
BBBY Bed Bath & Beyond Inc
Go

Health Care : Pharmaceuticals | Large Cap Growth
Company profile

Eli Lilly and Company is engaged in a drug manufacturing business. The Company discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Trajenta, and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. Its immunology products include Olumiant, Baricitinib, and Taltz. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab, Cialis, and Forteo. It maintains special business groups to service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. It manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. Its products are sold in about 120 countries.

Closing Price
$348.01
Day's Change
-1.72 (-0.49%)
Bid
--
Ask
--
B/A Size
--
Day's High
352.18
Day's Low
346.73
Volume
(Average)
Volume:
2,576,176

10-day average volume:
2,710,720
2,576,176

LLY's position in the Pharmaceuticals industry

Industry PeersLLYBMYZTSITCIRETA

Summary

Company ProfileEli Lilly and Company is engaged in a drug manufacturing business. The Company discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes...
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical...
Go to BMY summary
Zoetis Inc. is an animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices...
Go to ZTS summary
Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved...
Go to ITCI summary
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on identifying, developing, and commercializing therapies. The Company is also focused on providing...
Go to RETA summary
52-Week Change

VS. INDUSTRY
46.05%
17.15%
-15.23%
3.43%
55.73%
Market Cap

VS. INDUSTRY
$332.3B
$155.6B
$77.1B
$4.6B
$1.5B
Beta

VS. INDUSTRY
0.4
0.4
0.7
1.1
1.2
Dividend Yield

VS. INDUSTRY
1.29%
3.12%
0.91%
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
52.56x
23.85x
37.83x
--
--
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$29.2B
$46.7B
$8.0B
$188.1M
$3.1M
Profit Margin

VS. INDUSTRY
20.63%
14.32%
25.78%
-158.39%
-9,901.05%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
18.88%
3.27%
20.99%
--
--
Revenue Growth (TTM)

VS. INDUSTRY
5.34%
2.79%
5.13%
166.50%
-77.09%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.